Jim Cramer: 'Hold On' To Builders FirstSource, 'Here's The Problem' With Viking Therapeutics
Portfolio Pulse from Avi Kapoor
Jim Cramer discussed several stocks on CNBC's 'Mad Money Lightning Round.' He praised Vertex Pharmaceuticals for its strong performance and revenue guidance increase. Builders FirstSource is recommended as a buy, while Viking Therapeutics faces challenges due to high factory costs. Serve Robotics is not recommended due to its financial losses.
August 29, 2024 | 12:42 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Serve Robotics is not recommended by Jim Cramer due to financial losses, despite recent $20 million private placement.
Cramer's lack of recommendation and financial losses suggest potential negative impact on stock price.
CONFIDENCE 75
IMPORTANCE 50
RELEVANCE 50
NEGATIVE IMPACT
Viking Therapeutics faces challenges due to high factory costs, despite better-than-expected Q2 EPS results.
High factory costs present a significant challenge, potentially impacting stock negatively despite good EPS results.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 60
POSITIVE IMPACT
Builders FirstSource is recommended as a buy by Jim Cramer, despite missing sales estimates, due to strong EPS performance.
Cramer's positive outlook and strong EPS performance suggest potential for stock price increase, despite sales miss.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 70
POSITIVE IMPACT
Vertex Pharmaceuticals reported strong Q2 revenues and raised its 2024 product revenue guidance, leading to a 2% stock price increase.
Vertex's strong Q2 performance and increased revenue guidance are positive indicators, likely contributing to the stock's 2% rise.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 80